4.43
+2.78%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Covalon Technologies
Its shares trade on TSX Venture under the ticker COV.V. It has been listed since 3 September 2004. In the fiscal year to 30 September 2025, it reported revenue of C$32.8m and net income of C$2.1m. At that date it held total assets of C$36.1m and shareholders' equity of C$30.7m.
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of patent-protected medical products. The company is headquartered in Mississauga, Ontario. The company went IPO on 2004-09-03. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. The company leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon’s name and by developing and commercializing medical products for other medical companies under development and license contracts. The company provides a range of specialized medical devices, medical dressings and advanced medical technology designed for infection prevention, complex wound closure and perioperative care. Its perioperative care solutions provide antimicrobial protection of pre-operative skin, through postoperative incision care to scar prophylaxis.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Sept 2004
- Website
- covalon.com ↗
Leadership
Pay as last reported
- Mr. Amir BoloorExecutive Chairman of the Board, since 2020C$287,135
- Mr. Abe SchwartzChairman of the Board, since 2008C$18,000
- Mr. Brent AshtonChief Executive Officer, Director, since 2024C$590,698
- Ms. Katie MartinovichInterim Chief Financial OfficerC$225,321
- Ms. Kim CrooksChief Operating Officer, DirectorC$367,642
- Mr. Joseph CordianoLead Independent DirectorC$60,000
- Mr. Martin GoldfarbDirectorC$45,600
- Dr. Samantha NuttIndependent DirectorC$45,600
- Mr. Ronald SmithIndependent DirectorC$60,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Mississauga, Ontario with a focus on biotechnology within the healthcare sector.
- Offers patented medical products for wound care, infection prevention, and medical device coatings.
- Develops both branded products and licenses technology to other medical companies.
Weaknesses
- No specific financial data provided for performance evaluation.
- No mention of market share or competitive positioning within the biotechnology industry.
- No details on research and development expenses or innovation pipeline.
Opportunities
- Expansion of patented technologies into new medical applications and markets.
- Growing demand for advanced wound care and infection prevention solutions.
- Potential for increased partnerships with other medical companies for product development.
Threats
- Dependence on patent-protected technologies which may face legal challenges.
- Competition from other biotechnology firms in the healthcare sector.
- Market volatility in the healthcare industry affecting investment and growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.